By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: A Drive for Prostate Cancer Research: Dedicated Research at Sand Lake Imaging Aims to Help Cure Prostate Cancer
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Specialties > Radiology > A Drive for Prostate Cancer Research: Dedicated Research at Sand Lake Imaging Aims to Help Cure Prostate Cancer
RadiologySpecialtiesTechnology

A Drive for Prostate Cancer Research: Dedicated Research at Sand Lake Imaging Aims to Help Cure Prostate Cancer

Siemens Healthcare
Siemens Healthcare
Share
6 Min Read
Image
SHARE

ImageProstate cancer is the second most common cause of deaths from cancer in American men. About one in 36 will die of prostate cancer1. Dr. Stephen M. Bravo’s father, a radiologist at Yale, was one of them. Bravo is Medical Director at Sand Lake Imaging, Orlando, Florida, USA. He is passionate about trying to make sure that what he experienced is not experienced by other prostate cancer patients.

ImageProstate cancer is the second most common cause of deaths from cancer in American men. About one in 36 will die of prostate cancer1. Dr. Stephen M. Bravo’s father, a radiologist at Yale, was one of them. Bravo is Medical Director at Sand Lake Imaging, Orlando, Florida, USA. He is passionate about trying to make sure that what he experienced is not experienced by other prostate cancer patients.

Earlier Detection of Metastases
Stephen M. Bravo, MD, and his team at Sand Lake Imaging hope to help cure prostate cancer – or at least transform it from an acute and mortal threat into a manageable chronic disease. His team was therefore in no way astonished when Bravo suggested they participate in a clinical study aimed at earlier detection of lymph node metastases.

Detecting Abnormal Lymph Nodes
When looking at the background of the study, Dr. Bravo had to rely on size criteria such as whether a lymph node achieved the size of at least one centimeter in all dimensions. Lymph nodes smaller than one centimeter may also harbor disease, especially metastases from prostate cancer, but there was no unique tool to be able to detect this disease early on. And even when a lymph node reached one centimeter in size, it was uncertain as to whether that represented a myelodysplastic invasion from metastatic disease or whether it was just a reactive, normal inflammatory process that frequently occurs in the body, especially in reaction to prostatectomy or radiation therapy. Dr. Bravo states that their goal was to define early lymphatic disease before it became metastatic to a size greater than one centimeter. This requires both excellent imaging capabilities as well as efficient quantitative 3D visualization tools.

More Read

dental implant myths that must go away
Debunking the 9 Biggest Myths of Dental Implants
Book Review: The Future of Health-Care Delivery by Stephen Schimpff
Asset Management the Siemens Way
The Future of Medicine: How Cloud Computing Is Paving the Way to Better Medical Research
Telomeres Point to New Osteoarthritis Therapies

Precision Imaging for Prostate Cancer
Dr. Bravo and his team are using Feraheme (Ferumoxytol) to detect metastatic disease in nodes as small as three millimeters. This drug accumulates in normal lymph nodes but is not absorbed in prostate cancer cells within the lymph nodes. Patients are given the contrast agent on their first day of imaging exams; they also have a computed tomography (CT) scan to localize the smallest of the lymph nodes. Feraheme takes 18 to 24 hours to show up as a hyper-intense lesion under magnetic resonance imaging (MRI). So, the actual MRI imaging is done on the second day using a 3-tesla system.

Multiple Imaging Modalities
The CT images are then used to determine that the lymph nodes follow the appropriate signal characteristics on the MRI images – that is, that they all absorb the Feraheme contrast agent and show up accordingly on the MRI images. Positive lymph nodes that do not show up on the MRI scan as having absorbed the contrast agent are subsequently treated at affiliated clinics using precise radiation therapy. The next day, patients have a positron emission tomography/computed tomography (PET∙CT) scan with F18 Sodium Fluoride. PET∙CT is an important diagnostic tool for evaluating body metastatic disease and its accuracy in determining micro-metastatic disease has been proven in several studies for various cancers.

Multimodality Challenges
With three modalities and gigabytes of images, however, preparation, diagnosing, and reporting of images could have been complicated. According to Dr. Bravo, the  biggest challenge for technologists in radiology is the  constant pressure to be effective. syngo®.via3 helps  with this challenge by making sure that the data sent over to the radiologists is right the first time, and is concise. One of the reasons why Sand Lake Imaging decided to go with the imaging software syngo.via was because they don’t have a 3D lab with staff processing images and sending them to the radiologists. Dr. Bravo felt that there is significant added value when combining the different modalities with syngo.via, enabling a far more precise and efficient workflow.

In conclusion, thanks to syngo.via, the team of Sand lake Imaging could not have carried out the Feraheme research.

Read more articles like this one on Medical Solutions Online – the Magazine for Healthcare Leadership. http://sie.ag/1bGqJIg

1 http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics. Last accessed Oct 4th, 2013
2 The outcomes achieved by the Siemens customers described herein were achieved in the customer’s unique setting.   Since there is no “typical” hospital and many variables exist (e.g. hospital size, case mix, level of IT adoption) there can be no guarantee that others will achieve the same results.
3 syngo.via can be used as a standalone device or together with a variety of syngo.via-based software options, which are medical devices in their own rights.


TAGGED:prostate cancerSiemens
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

a woman walking on the hallway
6 Easy Healthcare Ways to Sit Less and Move More Every Day
Health
September 9, 2025
Clinical Expertise
Healthcare at a Crossroads: Why Leadership Matters More Than Ever
Global Healthcare
September 9, 2025
travel nurse in north carolina
Balancing Speed and Scope: Choosing the Nursing Degree That Fits Your Goals
Nursing
September 1, 2025
intimacy
How to Keep Intimacy Comfortable as You Age
Relationship and Lifestyle Senior Care
September 1, 2025

You Might also Like

Telemonitoring at Work in the Netherlands

November 25, 2013

Bone Density Tests – Too Many Not a Good Thing

March 17, 2012

What Are the Hidden Dangers of Varicose Veins?

March 8, 2016

Over $5 Billion in Medical Technology Financing in 2011

December 31, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?